Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Stock Short Interest Report for October

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a significant decline in short interest in October. As of October 30th, there was short interest totaling 4,226 shares, a decline of 92.6% from the October 15th total of 57,367 shares. Based on an average daily volume of 50,823 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are sold short.

Otsuka Stock Down 1.0%

Shares of OTCMKTS:OTSKY traded down $0.39 during mid-day trading on Tuesday, hitting $37.68. 47,319 shares of the company traded hands, compared to its average volume of 41,408. The firm has a market cap of $40.48 billion, a P/E ratio of 16.17, a PEG ratio of 2.75 and a beta of 0.08. The firm’s 50 day simple moving average is $37.29 and its 200 day simple moving average is $35.10. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.65 and a current ratio of 2.21. Otsuka has a 52-week low of $26.11 and a 52-week high of $40.92.

Otsuka (OTCMKTS:OTSKY) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. The firm had revenue of $4.51 billion during the quarter, compared to the consensus estimate of $4.42 billion. Otsuka had a return on equity of 11.90% and a net margin of 14.36%. On average, equities analysts anticipate that Otsuka will post 2.21 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Otsuka from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.